AAPL315.34-0.88 (-0.28%) ▼|ABBV250.91+2.13 (+0.86%) ▲|ABT105.23-0.29 (-0.27%) ▼|ACN175.80-3.23 (-1.80%) ▼|ADBE254.86-2.40 (-0.93%) ▼|AMAT468.85-3.94 (-0.83%) ▼|AMD521.10+15.36 (+3.04%) ▲|AMGN391.27-1.90 (-0.48%) ▼|AMT175.43-0.30 (-0.17%) ▼|AMZN252.40-4.57 (-1.78%) ▼|AVGO364.38-4.18 (-1.13%) ▼|AXP321.80-4.30 (-1.32%) ▼|BA206.42-4.31 (-2.05%) ▼|BAC62.67+0.28 (+0.45%) ▲|BKNG173.43-6.87 (-3.81%) ▼|BLK1,072.03-23.34 (-2.13%) ▼|BMY64.41-0.28 (-0.43%) ▼|BNY162.51-0.34 (-0.21%) ▼|BRK-B506.72+0.89 (+0.18%) ▲|C137.80+1.06 (+0.78%) ▲|CAT815.56-6.92 (-0.84%) ▼|CL88.03-0.38 (-0.43%) ▼|CMCSA24.59-1.74 (-6.61%) ▼|COF210.86-3.10 (-1.45%) ▼|COP136.53+1.49 (+1.10%) ▲|COST902.60-7.58 (-0.83%) ▼|CRM244.16-4.96 (-1.99%) ▼|CSCO109.43+0.26 (+0.24%) ▲|CVS95.38-0.69 (-0.72%) ▼|CVX213.81+4.01 (+1.91%) ▲|DE677.21-3.52 (-0.52%) ▼|DHR204.85-0.38 (-0.19%) ▼|DIS104.18-0.88 (-0.84%) ▼|DUK120.43-0.81 (-0.67%) ▼|EMR150.34-1.81 (-1.19%) ▼|FDX309.19-4.94 (-1.57%) ▼|GD352.67-3.91 (-1.10%) ▼|GE325.42-9.49 (-2.83%) ▼|GEV951.04-20.27 (-2.09%) ▼|GILD145.65-0.99 (-0.68%) ▼|GM83.76-2.03 (-2.37%) ▼|GOOG328.38-7.00 (-2.09%) ▼|GOOGL330.65-7.71 (-2.28%) ▼|GS1,028.78-7.75 (-0.75%) ▼|HD310.45-3.25 (-1.04%) ▼|HON204.93-3.31 (-1.59%) ▼|IBM239.94+7.85 (+3.38%) ▲|INTC106.24+1.77 (+1.69%) ▲|INTU313.94-4.99 (-1.56%) ▼|ISRG353.24+3.08 (+0.88%) ▲|JNJ267.08-2.04 (-0.76%) ▼|JPM354.71+1.20 (+0.34%) ▲|KO87.55-0.81 (-0.92%) ▼|LIN466.65-1.73 (-0.37%) ▼|LLY1,124.21+0.30 (+0.03%) ▲|LMT524.46-11.69 (-2.18%) ▼|LOW198.60-2.20 (-1.10%) ▼|LRCX315.84-4.58 (-1.43%) ▼|MA567.50-3.39 (-0.59%) ▼|MCD253.48-2.33 (-0.91%) ▼|MDLZ62.42+0.79 (+1.28%) ▲|MDT91.89-0.50 (-0.54%) ▼|META653.69+40.21 (+6.55%) ▲|MMM164.40-3.12 (-1.86%) ▼|MO67.89-0.28 (-0.41%) ▼|MRK147.53-0.93 (-0.63%) ▼|MS215.35-0.89 (-0.41%) ▼|MSFT491.65-2.30 (-0.47%) ▼|MU1,027.77+27.51 (+2.75%) ▲|NEE82.65-1.18 (-1.41%) ▼|NFLX76.03-0.74 (-0.96%) ▼|NKE37.35-0.75 (-1.97%) ▼|NOW131.11-3.10 (-2.31%) ▼|NVDA223.67-2.06 (-0.91%) ▼|ORCL161.63-0.89 (-0.55%) ▼|PEP136.69-1.76 (-1.27%) ▼|PFE27.78-0.01 (-0.04%) ▼|PG142.64-2.94 (-2.02%) ▼|PLTR169.53-0.77 (-0.45%) ▼|PM185.71+0.98 (+0.53%) ▲|QCOM176.40+2.31 (+1.33%) ▲|RTX197.55-1.26 (-0.63%) ▼|SBUX100.04-1.97 (-1.93%) ▼|SCHW106.54-0.33 (-0.31%) ▼|SO88.34-0.65 (-0.73%) ▼|SPG204.53-5.10 (-2.43%) ▼|T25.15-0.45 (-1.76%) ▼|TMO605.69+2.67 (+0.44%) ▲|TMUS177.34-4.35 (-2.39%) ▼|TSLA367.81-0.35 (-0.10%) ▼|TXN261.59+2.67 (+1.03%) ▲|UBER71.08-2.05 (-2.80%) ▼|UNH393.06-7.78 (-1.94%) ▼|UNP284.74-3.71 (-1.29%) ▼|UPS99.22-1.26 (-1.25%) ▼|USB62.11-0.38 (-0.61%) ▼|V367.39-1.25 (-0.34%) ▼|VZ49.74-0.67 (-1.33%) ▼|WFC89.67+1.71 (+1.94%) ▲|WMT105.83-0.22 (-0.21%) ▼|XOM164.23+3.57 (+2.22%) ▲|AAPL315.34-0.88 (-0.28%) ▼|ABBV250.91+2.13 (+0.86%) ▲|ABT105.23-0.29 (-0.27%) ▼|ACN175.80-3.23 (-1.80%) ▼|ADBE254.86-2.40 (-0.93%) ▼|AMAT468.85-3.94 (-0.83%) ▼|AMD521.10+15.36 (+3.04%) ▲|AMGN391.27-1.90 (-0.48%) ▼|AMT175.43-0.30 (-0.17%) ▼|AMZN252.40-4.57 (-1.78%) ▼|AVGO364.38-4.18 (-1.13%) ▼|AXP321.80-4.30 (-1.32%) ▼|BA206.42-4.31 (-2.05%) ▼|BAC62.67+0.28 (+0.45%) ▲|BKNG173.43-6.87 (-3.81%) ▼|BLK1,072.03-23.34 (-2.13%) ▼|BMY64.41-0.28 (-0.43%) ▼|BNY162.51-0.34 (-0.21%) ▼|BRK-B506.72+0.89 (+0.18%) ▲|C137.80+1.06 (+0.78%) ▲|CAT815.56-6.92 (-0.84%) ▼|CL88.03-0.38 (-0.43%) ▼|CMCSA24.59-1.74 (-6.61%) ▼|COF210.86-3.10 (-1.45%) ▼|COP136.53+1.49 (+1.10%) ▲|COST902.60-7.58 (-0.83%) ▼|CRM244.16-4.96 (-1.99%) ▼|CSCO109.43+0.26 (+0.24%) ▲|CVS95.38-0.69 (-0.72%) ▼|CVX213.81+4.01 (+1.91%) ▲|DE677.21-3.52 (-0.52%) ▼|DHR204.85-0.38 (-0.19%) ▼|DIS104.18-0.88 (-0.84%) ▼|DUK120.43-0.81 (-0.67%) ▼|EMR150.34-1.81 (-1.19%) ▼|FDX309.19-4.94 (-1.57%) ▼|GD352.67-3.91 (-1.10%) ▼|GE325.42-9.49 (-2.83%) ▼|GEV951.04-20.27 (-2.09%) ▼|GILD145.65-0.99 (-0.68%) ▼|GM83.76-2.03 (-2.37%) ▼|GOOG328.38-7.00 (-2.09%) ▼|GOOGL330.65-7.71 (-2.28%) ▼|GS1,028.78-7.75 (-0.75%) ▼|HD310.45-3.25 (-1.04%) ▼|HON204.93-3.31 (-1.59%) ▼|IBM239.94+7.85 (+3.38%) ▲|INTC106.24+1.77 (+1.69%) ▲|INTU313.94-4.99 (-1.56%) ▼|ISRG353.24+3.08 (+0.88%) ▲|JNJ267.08-2.04 (-0.76%) ▼|JPM354.71+1.20 (+0.34%) ▲|KO87.55-0.81 (-0.92%) ▼|LIN466.65-1.73 (-0.37%) ▼|LLY1,124.21+0.30 (+0.03%) ▲|LMT524.46-11.69 (-2.18%) ▼|LOW198.60-2.20 (-1.10%) ▼|LRCX315.84-4.58 (-1.43%) ▼|MA567.50-3.39 (-0.59%) ▼|MCD253.48-2.33 (-0.91%) ▼|MDLZ62.42+0.79 (+1.28%) ▲|MDT91.89-0.50 (-0.54%) ▼|META653.69+40.21 (+6.55%) ▲|MMM164.40-3.12 (-1.86%) ▼|MO67.89-0.28 (-0.41%) ▼|MRK147.53-0.93 (-0.63%) ▼|MS215.35-0.89 (-0.41%) ▼|MSFT491.65-2.30 (-0.47%) ▼|MU1,027.77+27.51 (+2.75%) ▲|NEE82.65-1.18 (-1.41%) ▼|NFLX76.03-0.74 (-0.96%) ▼|NKE37.35-0.75 (-1.97%) ▼|NOW131.11-3.10 (-2.31%) ▼|NVDA223.67-2.06 (-0.91%) ▼|ORCL161.63-0.89 (-0.55%) ▼|PEP136.69-1.76 (-1.27%) ▼|PFE27.78-0.01 (-0.04%) ▼|PG142.64-2.94 (-2.02%) ▼|PLTR169.53-0.77 (-0.45%) ▼|PM185.71+0.98 (+0.53%) ▲|QCOM176.40+2.31 (+1.33%) ▲|RTX197.55-1.26 (-0.63%) ▼|SBUX100.04-1.97 (-1.93%) ▼|SCHW106.54-0.33 (-0.31%) ▼|SO88.34-0.65 (-0.73%) ▼|SPG204.53-5.10 (-2.43%) ▼|T25.15-0.45 (-1.76%) ▼|TMO605.69+2.67 (+0.44%) ▲|TMUS177.34-4.35 (-2.39%) ▼|TSLA367.81-0.35 (-0.10%) ▼|TXN261.59+2.67 (+1.03%) ▲|UBER71.08-2.05 (-2.80%) ▼|UNH393.06-7.78 (-1.94%) ▼|UNP284.74-3.71 (-1.29%) ▼|UPS99.22-1.26 (-1.25%) ▼|USB62.11-0.38 (-0.61%) ▼|V367.39-1.25 (-0.34%) ▼|VZ49.74-0.67 (-1.33%) ▼|WFC89.67+1.71 (+1.94%) ▲|WMT105.83-0.22 (-0.21%) ▼|XOM164.23+3.57 (+2.22%) ▲|
24.6 C
New York
Thursday, September 10, 2026

Tag: diseases

newssourceFORcompanyinformationcontent1releasesmarket

Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA’s 85th Scientific Sessions

SAN FRANCISCO and SUZHOU, China, June 12, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and...

PEPG Investor Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against PepGen Inc.

SAN DIEGO, June 12, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise...

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival.

Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses

-- Breadth of presentations, including one oral and two flash talks, showcase Blueprint Medicines' leadership role in advancing care for patients with systemic mastocytosis...

RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit

SAN DIEGO, June 12, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT)...

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

PITTSBURGH, June 12, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) will report second quarter 2025 financial results on Thursday, August 7, 2025. Company executives will...

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

– Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients –

Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions

SINGAPORE, June 12, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the expansion of its existing supply and distribution agreement...

European Commission Grants Orphan Drug Designation to Florbetaben (18F) for Diagnosis of ATTR Amyloidosis

Florbetaben (18F) has been granted Orphan drug designation for the diagnosis of ATTR amyloidosisFlorbetaben (18F) previously received orphan drug designation as a diagnostic agent...

Bay Area Lyme Foundation Announces National Winner of the 2025 Emerging Leader Award to Develop a Much-Needed Rapid, Low-Cost, Easy-to-Use Lyme Disease Test

Winner Chao Wang of Arizona State University will receive $150,000 to evaluate a unique diagnostic that uses gold nanoparticles and has been proven in other infectious diseases 
Winner Chao Wang of Arizona State University will receive $150,000 to evaluate a unique diagnostic that uses gold nanoparticles and has been proven in other infectious diseases

Lunit AI Used Again for Mass Screening During 2025 Hajj Season in Saudi Arabia

Saudi Government and Seha Virtual Hospital selected Lunit INSIGHT CXR to detect respiratory diseases among millions of pilgrims, supporting Saudi Arabia's Vision 2030 healthcare strategy SEOUL,...

Pharmaceutical Industry Calls on G7 to Prioritize Innovation as Strategic Pillar for Health, Growth and Security

GENEVA and OTTAWA, ON, June 12, 2025 /CNW/ - Ahead of the upcoming G7 Leaders' Summit, the global pharmaceutical industry, represented by the International...

Mosquito Joe® Urges Prevention as Summer Mosquito Threat Looms

Leading Pest Control Company Encourages Action Ahead of National Mosquito Control Awareness Week VIRGINIA BEACH, Va., June 12, 2025 /PRNewswire/ -- As the nation prepares...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDiseases

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers